<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cancer-related fatigue: Prevalence, screening, and clinical assessment</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cancer-related fatigue: Prevalence, screening, and clinical assessment</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cancer-related fatigue: Prevalence, screening, and clinical assessment</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carmen P Escalante, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul J Hesketh, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 31, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Fatigue is a common problem in cancer patients. A majority of patients will experience some level of fatigue during their course of treatment, and approximately one-third will have persistent fatigue for a number of years posttreatment [<a href="#rid1">1,2</a>]. Cancer-related fatigue (CRF) profoundly affects quality of life (QOL) of both patients and their caregivers, including physical, psychosocial, and economic/occupational aspects [<a href="#rid3">3,4</a>]. Furthermore, fatigue is routinely identified by patients as one of the most distressing symptoms associated with cancer and its treatment, yet fatigue has been consistently underreported and overlooked as a potentially remediable cause of treatment-related morbidity [<a href="#rid5">5</a>]. More recently, screening for and treatment of CRF during therapy and during the period of cancer survivorship has become a major focus of supportive care in oncology and is the subject of guidelines from several expert groups, including the American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network [<a href="#rid6">6-8</a>].</p><p>Here we will review the contributory factors and pathogenesis of CRF, and screening for as well as clinical assessment of patients with CRF. Treatment of CRF and issues surrounding fatigue that are specific to palliative care patients are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/2813.html" rel="external">"Cancer-related fatigue: Treatment"</a> and  <a class="medical medical_review" href="/d/html/14239.html" rel="external">"Overview of fatigue in palliative care"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">DEFINITION</span><span class="headingEndMark"> — </span>CRF is defined as a distressing, persistent, subjective sense of physical, emotional, and/or cognitive tiredness or exhaustion related to cancer or cancer treatment that is not proportional to recent activity and that significantly interferes with usual functioning [<a href="#rid6">6</a>]. CRF differs from the fatigue that accompanies everyday life, which is usually temporary and relieved by rest.</p><p>The term asthenia has been proposed to describe the condition of chronic pathologic tiredness in patients with cancer [<a href="#rid9">9</a>]. However, the term fatigue has gained widespread acceptance in the medical literature and is preferentially used in the National Cancer Institute (NCI) toxicity grading scale that covers fatigue, asthenia, and malaise  (<a class="graphic graphic_table graphicRef60072" href="/d/graphic/60072.html" rel="external">table 1</a>).</p><p>Specific diagnostic criteria have been proposed for defining CRF as an independent entity in the International Classification of Diseases, 10th revision (ICD-10) [<a href="#rid10">10,11</a>]. At least 6 of 11 criteria must be met to make the diagnosis of CRF  (<a class="graphic graphic_table graphicRef61574" href="/d/graphic/61574.html" rel="external">table 2</a>). In studies of diverse patient populations, approximately 10 to 26 percent of subjects are diagnosed as having CRF using this definition [<a href="#rid12">12-15</a>].</p><p>The use of diagnostic criteria such as these provides a greater degree of specificity than the simple question "Do you feel tired?" as was used in two national CRF prevalence studies and that resulted in spuriously high prevalence figures [<a href="#rid16">16,17</a>]. (See <a class="local">'Prevalence and time course'</a> below.)</p><p>However, the formal diagnostic criteria as outlined in the ICD-10  (<a class="graphic graphic_table graphicRef61574" href="/d/graphic/61574.html" rel="external">table 2</a>) are not in widespread use, and patients do not necessarily need to have a minimum number of criteria to receive a clinical diagnosis of CRF. Their use is not recommended in guidelines for screening and assessment of CRF from expert groups, including the National Comprehensive Cancer Network (NCCN) [<a href="#rid6">6,7,18</a>].</p><p class="headingAnchor" id="H3"><span class="h1">PREVALENCE AND TIME COURSE</span><span class="headingEndMark"> — </span>CRF is a common problem. A majority of patients will experience some level of fatigue during their course of treatment, and approximately one-third will have persistent fatigue for a number of years posttreatment [<a href="#rid1">1,2,19</a>].</p><p>The true incidence of CRF in cancer patients is difficult to ascertain; published studies are restricted to prevalence data. Estimates are that CRF affects between 15 and 90 percent of cancer patients overall [<a href="#rid12">12,16,17,20-33</a>] and more than 75 percent of those with advanced cancer or bone metastases [<a href="#rid20">20,34</a>]. The wide range of these estimates likely reflects variable diagnostic criteria used to define CRF.</p><p>The prevalence and severity of CRF were studied in two United States national surveys commissioned by the Fatigue Coalition, a multidisciplinary group of practitioners, researchers, and patient advocates [<a href="#rid16">16,17</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In the first survey, 419 cancer patients who were members of 1700 randomly selected American families were interviewed by telephone [<a href="#rid16">16</a>]. Fatigue was defined as a positive response to the single question "Do you feel tired?" The majority had solid tumors, and treatment consisted of chemotherapy (59 percent), radiation therapy ([RT] 63 percent), or both (24 percent). More than one-half had received therapy within the last year. In a separate mail survey, 197 of 600 randomly sampled oncologists responded to a questionnaire assessing perceptions and attitudes concerning CRF.</p><p></p><p class="bulletIndent1">Overall, 74 percent of patients reported fatigue at some point during the course of their illness, with 32 percent reporting daily fatigue. However, only 50 percent of patients had discussed fatigue with their clinician, and in only one-fourth of cases was any intervention proposed. Patients and oncologists disagreed on the importance of CRF. Although doctors believed that pain affected patients to a greater degree than fatigue, patients thought that CRF adversely affected their daily lives to a greater degree than pain.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similar results were noted in a second telephone survey of 379 patients who had received chemotherapy with or without RT for some form of malignancy, identified from a representative sample of 6125 families obtained from the US Bureau of the Census [<a href="#rid17">17</a>]. Fatigue, defined the same way as in the first study, was present on at least some days of the month during chemotherapy in 76 percent of patients, with 30 percent suffering from fatigue on a daily basis. Patients reported fatigue as the symptom that most affected quality of life (QOL), followed by nausea, depression, and pain. The economic impact of CRF was considerable. Of the 177 employed patients, 75 percent changed their employment status as a result of fatigue, and 65 percent reported that their caregivers had to take at least one day (mean 4.5 days) off from work in a typical month.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Comparable findings also were noted in a survey of patients and health care practitioners conducted by the All-Ireland Fatigue Coalition [<a href="#rid35">35</a>]. However, all of these surveys consist of retrospective cross-sectional data and are biased by recall and the use of nonvalidated diagnostic criteria.</p><p></p><p>As expected, a lower prevalence of CRF has been found in studies applying stricter diagnostic criteria [<a href="#rid12">12,13,36</a>]. This was illustrated in a validation study of the CRF diagnostic criteria being proposed for use in the International Classification of Diseases, 10th revision (ICD-10)  (<a class="graphic graphic_table graphicRef61574" href="/d/graphic/61574.html" rel="external">table 2</a>) that was carried out in 379 individuals receiving chemotherapy with or without RT [<a href="#rid12">12</a>]. Overall, 141 patients (37 percent) had fatigue for at least two weeks in the prior month (ie, one of the proposed criteria), although only 66 (17 percent) met the proposed definition of CRF.</p><p>An additional problem with prevalence data is that CRF tends to fluctuate over the course of cancer treatment. For patients receiving chemotherapy, CRF is commonly cyclic and worst when blood counts are at their nadir (usually 10 to 14 days following treatment initiation). In contrast, the intensity of CRF in patients undergoing RT typically peaks toward the end of therapy, gradually decreasing thereafter [<a href="#rid30">30,37-43</a>].</p><p>Although CRF is most prevalent during active cancer therapy, a sense of fatigue may persist in survivors for months or even years after cessation of treatment [<a href="#rid1">1,2,19,32,41,44-54</a>]. The available data suggest that up to one-third of cancer survivors will have persistent posttreatment fatigue, which can be severe [<a href="#rid1">1,2,19</a>]. A small minority of patients who are presumably cured of their cancer are so debilitated by fatigue that they are still unable to work or regain their premorbid lifestyles years after completing treatment. Because of the lack of objective findings, many have problems maintaining disability status, causing additional stress and anxiety for themselves and their caregivers.</p><p>Given the persistence of fatigue following completion of active cancer therapy, guidelines from expert groups including the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) recommend screening for fatigue at the end of primary therapy and as clinically indicated (at least annually) during the period of survivorship care [<a href="#rid6">6,18</a>].</p><p class="headingAnchor" id="H5"><span class="h1">MAIN CONTRIBUTORY FACTORS</span><span class="headingEndMark"> — </span>Although typically multifactorial, the main contributory factors to CRF include the following [<a href="#rid6">6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Cancer therapy, including cytotoxic agents, biologic response modifiers, molecularly targeted therapies (especially those targeting the vascular endothelial growth factor and epidermal growth factor receptor), hormonal therapies (eg, androgen deprivation therapy), and RT</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Progressive tumor growth</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Unrelieved pain</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anemia</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Metabolic/nutritional/hormonal issues, such as poor nutrition, fluid/electrolyte disturbances, hypothyroidism, male hypogonadism, menopause, and dehydration</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Comorbidities, including cardiac, respiratory, renal, hepatic, and endocrine dysfunction, infection, neuromuscular disorders</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Medication side effects, especially sedation from opioid analgesics</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Deconditioning</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Depressed mood, emotional distress, and sleep disturbance</p><p></p><p class="headingAnchor" id="H8909289"><span class="h2">Cancer therapy and pathogenesis of fatigue</span><span class="headingEndMark"> — </span>In many cases, the mechanisms that are responsible for CRF are poorly understood. Major obstacles to defining the relevant pathophysiology include the inherent subjectivity of fatigue, the difficulty in establishing objective behavioral correlates, and the wide variety of phenomena (including conditions that are unrelated to cancer or its treatment) that contribute to fatigue [<a href="#rid55">55</a>].</p><p>A variety of pathophysiologic hypotheses have been proposed for CRF, although none have been proven:</p><p class="bulletIndent1"><span class="glyph">●</span>Direct central nervous system toxicity of cancer treatment (ie, drugs that cross the blood-brain barrier, cranial irradiation).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anemia from blood loss or chemotherapy-related myelosuppression.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Loss of muscle mass, defective muscle energy metabolism, and/or abnormalities in the generation or use of adenosine triphosphate (ATP) [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neurophysiologic skeletal muscle changes (the so-called vagal afferent hypothesis) [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic stress response, possibly mediated through the hypothalamic pituitary axis [<a href="#rid23">23,56</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Systemic inflammatory response [<a href="#rid57">57-60</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immune activation associated with production of proinflammatory cytokines [<a href="#rid61">61,62</a>] and/or circulating T cells [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Disrupted sleep or circadian rhythms [<a href="#rid64">64-68</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hormonal changes (eg, premature menopause in women).</p><p></p><p>A detailed description of these hypotheses and the data upon which they are based is beyond the scope of this review and provided elsewhere [<a href="#rid55">55,62,69-71</a>]. What follows is a brief overview of the mechanisms underlying CRF that are directly related to cancer therapy.</p><p class="headingAnchor" id="H6"><span class="h3">Chemotherapy and molecularly targeted therapy</span><span class="headingEndMark"> — </span>Chemotherapy and molecularly targeted therapy with small molecule tyrosine kinase inhibitors or therapeutic monoclonal antibodies may contribute directly to the development of CRF. Among the agents that are most commonly associated with fatigue are <a class="drug drug_general" data-topicid="9209" href="/d/drug information/9209.html" rel="external">cetuximab</a> and <a class="drug drug_general" data-topicid="10095" href="/d/drug information/10095.html" rel="external">thalidomide</a> (80 to 90 percent), <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a>, <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a>, <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a>, and <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> (30 to 50 percent), <a class="drug drug_general" data-topicid="8452" href="/d/drug information/8452.html" rel="external">fludarabine</a>, <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a>, <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a>, <a class="drug drug_general" data-topicid="10336" href="/d/drug information/10336.html" rel="external">panitumumab</a>, and <a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">alemtuzumab</a> (15 to 30 percent). Other conventional cytotoxic agents that cross the blood brain barrier (eg, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">ifosfamide</a>, <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a>, <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a>, <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a>, <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a>) may also induce fatigue via a direct neurotoxic effect [<a href="#rid72">72</a>].</p><p>These agents can also indirectly contribute to CRF by causing or interacting with other mechanisms that induce or exacerbate fatigue [<a href="#rid20">20</a>]. Examples include chemotherapy-induced premature menopause [<a href="#rid73">73,74</a>] and the higher rates of posttreatment fatigue that have been seen in patients receiving chemotherapy who have preexisting poor mental health [<a href="#rid75">75</a>]. (See  <a class="medical medical_review" href="/d/html/745.html" rel="external">"Overview of side effects of chemotherapy for early-stage breast cancer"</a>.)</p><p>Long-term effects of chemotherapy on organ function may also contribute to CRF. Some examples are sunitinib-induced hypothyroidism, chronic heart failure from anthracycline-induced cardiomyopathy, and bleomycin-related pulmonary dysfunction [<a href="#rid76">76</a>]. (See  <a class="medical medical_review" href="/d/html/86366.html" rel="external">"Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Thyroid dysfunction'</a> and  <a class="medical medical_review" href="/d/html/90854.html" rel="external">"Clinical manifestations, diagnosis, and treatment of anthracycline-induced cardiotoxicity"</a> and  <a class="medical medical_review" href="/d/html/107443.html" rel="external">"Risk and prevention of anthracycline cardiotoxicity"</a> and  <a class="medical medical_review" href="/d/html/4316.html" rel="external">"Bleomycin-induced lung injury"</a>.)</p><p class="headingAnchor" id="H7"><span class="h3">Biologic response modifiers</span><span class="headingEndMark"> — </span>Fatigue is nearly universal in patients receiving interferon (IFN) or interleukin-2 (IL-2) for melanoma or renal cell cancer.</p><p>Mechanisms that may contribute to this effect include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Disturbances of the hypothalamic-pituitary-adrenal axis, which can affect levels of plasma corticotropin (ACTH) and corticotrophin-releasing hormone, and ultimately the secretion of cortisol by the adrenal cortex [<a href="#rid77">77-79</a>]. This may be mediated through the production of proinflammatory cytokines or by a direct inhibition.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Effects on neurotransmitter levels (eg, dopamine, serotonin).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drug-induced hypothyroidism [<a href="#rid80">80-83</a>].</p><p></p><p class="headingAnchor" id="H8"><span class="h3">Androgen deprivation therapy</span><span class="headingEndMark"> — </span>Fatigue is a common problem in men undergoing androgen deprivation therapy for prostate cancer; the mechanism is unclear. The extent of fatigue does not seem to correlate with anemia, loss of lean muscle mass, or emotional cognitive issues. Inherited variations in genes that regulate immune function have been implicated [<a href="#rid84">84,85</a>]. (See  <a class="medical medical_review" href="/d/html/6927.html" rel="external">"Side effects of androgen deprivation therapy", section on 'Fatigue'</a>.)</p><p class="headingAnchor" id="H9"><span class="h3">Radiation therapy</span><span class="headingEndMark"> — </span>Fatigue is a common early and chronic side effect of RT. It is reported in up to 80 and 30 percent of patients during RT and at follow-up visits, respectively [<a href="#rid3">3,86-88</a>]. In general, fatigue tends to worsen during treatment.</p><p>Fatigue is most common in patients receiving cranial irradiation and presumably related to direct effects on normal brain parenchyma or radiation-induced edema. This is often enhanced by the concomitant use of high-dose glucocorticoids. Although most patients have mild to moderate fatigue, a rare somnolence syndrome has been described. The etiology of this rare complication of cranial irradiation is unclear. (See  <a class="medical medical_review" href="/d/html/7053.html" rel="external">"Acute complications of cranial irradiation", section on 'Fatigue'</a>.)</p><p>The pathophysiology underlying fatigue in patients undergoing RT to extracranial sites is unclear. Sometimes anemia is contributory, but other mechanisms are probably operative [<a href="#rid89">89</a>]. As examples, in patients treated for pelvic malignancies, severe diarrhea during treatment may exacerbate fatigue [<a href="#rid90">90</a>], hypothyroidism may be a consequence of neck irradiation [<a href="#rid91">91</a>], and fatigue may accompany the concurrent use of androgen deprivation therapy in men receiving RT for prostate cancer. Psychological mechanisms have been proposed to explain fatigue in women receiving RT for early breast cancer [<a href="#rid3">3</a>], whereas a decline in neuromuscular efficiency has been proposed among men undergoing RT for prostate cancer [<a href="#rid92">92</a>].</p><p class="headingAnchor" id="H10"><span class="h3">Surgery</span><span class="headingEndMark"> — </span>Among the potential contributory factors to postoperative fatigue are operative blood loss, medication effects, decreased ventilatory capacity, immobilization, infection, perioperative nutritional depletion, altered sleep patterns, and anxiety.</p><p class="headingAnchor" id="H11"><span class="h2">Anemia</span><span class="headingEndMark"> — </span>Anemia is common in cancer patients, both as a consequence of the cancer itself (anemia of chronic disease, iron deficiency anemia due to gastrointestinal blood loss) or its treatment (surgery, systemic therapy, and RT). The full spectrum of other causes of anemia also needs to be considered in these patients (ie, hemolysis, nutritional deficiency). (See  <a class="medical medical_review" href="/d/html/7149.html" rel="external">"Anemia of chronic disease/anemia of inflammation"</a> and  <a class="medical medical_review" href="/d/html/7133.html" rel="external">"Diagnostic approach to anemia in adults"</a> and  <a class="medical medical_review" href="/d/html/7140.html" rel="external">"Causes of anemia in patients with cancer"</a>.)</p><p>Although early studies were unable to demonstrate a clear correlation between hemoglobin levels and the severity of CRF, a direct relationship between anemia, fatigue, and quality of life (QOL) has been seen in later studies that used more refined evaluation instruments, such as the Functional Assessment of Cancer Therapy-Anemia (FACT-An) subscale  (<a class="graphic graphic_table graphicRef76886" href="/d/graphic/76886.html" rel="external">table 3</a>) [<a href="#rid9">9,93-97</a>]. Correction of anemia has been associated with an improvement in both health-related QOL and fatigue. (See  <a class="medical medical_review" href="/d/html/2813.html" rel="external">"Cancer-related fatigue: Treatment", section on 'Anemic patients'</a>.)</p><p class="headingAnchor" id="H8909583"><span class="h2">Emotional disturbance/mood disorder</span><span class="headingEndMark"> — </span>Fatigue seldom occurs by itself, and it commonly clusters with emotional distress, mood disorders, sleep disturbance, and/or pain [<a href="#rid98">98-102</a>]. In particular, there is a strong correlation between fatigue and depression [<a href="#rid67">67,103-108</a>], and in some cases, it may be difficult to distinguish between the two as the source of distress [<a href="#rid108">108,109</a>].</p><p>The precise relationship between CRF and emotional distress is not clear. Fatigue can be a symptom of depression and/or anxiety, but high levels of fatigue also can result in emotional distress when valued roles and activities are affected. Some data support the view that depression and fatigue, although linked, follow a different time course in patients with cancer [<a href="#rid110">110</a>] and that they respond differentially to therapeutic intervention [<a href="#rid111">111</a>]. As an example, placebo-controlled randomized trials in patients undergoing cancer treatment have failed to demonstrate any improvement in CRF in patients randomly assigned to receive an antidepressant despite its benefit in reducing symptoms of depression. (See  <a class="medical medical_review" href="/d/html/2813.html" rel="external">"Cancer-related fatigue: Treatment", section on 'Antidepressants'</a>.)</p><p class="headingAnchor" id="H8909589"><span class="h2">Sleep disturbance</span><span class="headingEndMark"> — </span>Sleep disturbances in patients with cancer range from hypersomnia to insomnia. Although patients undergoing active cancer treatment tend to spend greater amounts of time resting and sleeping than individuals without cancer, sleep patterns often are disrupted, resulting in poor quality of sleep [<a href="#rid64">64,112,113</a>]. Insomnia symptoms affect between 30 and 50 percent of cancer patients, and 20 to 40 percent meet the diagnostic criteria for insomnia syndrome [<a href="#rid114">114-118</a>]. Sleep-wake disturbances may persist in long-term survivors [<a href="#rid119">119</a>].</p><p>Poor sleep hygiene (eg, frequent daytime naps late in the day) may contribute to inadequate nighttime rest. Medications may also contribute to insomnia. Patients with a history suggestive of sleep apnea should be referred for formal sleep evaluation. (See  <a class="medical medical_review" href="/d/html/7684.html" rel="external">"Risk factors, comorbidities, and consequences of insomnia in adults"</a> and  <a class="medical medical_review" href="/d/html/7706.html" rel="external">"Clinical presentation and diagnosis of obstructive sleep apnea in adults"</a>.)</p><p class="headingAnchor" id="H433791"><span class="h1">SCREENING</span><span class="headingEndMark"> — </span>All patients with malignant disease should be screened for CRF at the initial visit, at the end of primary therapy, as clinically indicated (and at least annually) during follow-up survivor care, when the diagnosis of advanced disease is made, and at each chemotherapy visit [<a href="#rid6">6</a>]. Screening should be performed and documented using a quantitative or semiquantitative assessment. One example is a visual analog scale (VAS, "How would you rate your fatigue on a scale of 0 to 10?"), with 0 representing no fatigue and 10 the worst imaginable fatigue [<a href="#rid6">6-8,120</a>]. Mild, moderate, and severe fatigue are represented by scores of 1 to 3, 4 to 6, and 7 to 10, respectively.</p><p>Multiple other instruments have been developed and validated to quantify fatigue in patients with serious illness, including cancer  (<a class="graphic graphic_table graphicRef86228" href="/d/graphic/86228.html" rel="external">table 4</a>). Some of the more commonly used and best validated are the fatigue and anemia subscales of the Functional Assessment of Cancer Therapy instrument (FACT-F discussed above), the Brief Fatigue Inventory (BFI)  (<a class="graphic graphic_table graphicRef54810" href="/d/graphic/54810.html" rel="external">table 5</a>) [<a href="#rid120">120</a>], the bidimensional fatigue scale [<a href="#rid121">121,122</a>], the Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF) [<a href="#rid123">123</a>], and the European Organisation for Research and Treatment of Cancer Quality of Life questionnaire (EORTC QLQ C30), fatigue subscale [<a href="#rid124">124</a>].</p><p>Because fatigue is subjective, the clinician must rely upon patient self-reports to assess its presence and severity, which can then be supported by additional sources of information, such as physical examination, laboratory data, or the descriptions of family members. At least some data from the PROTECT randomized trial suggest that routine screening for fatigue using electronic symptom monitoring during treatment for metastatic cancer and subsequent intervention that is triggered by severe or worsening symptoms substantially improves patient-reported fatigue outcomes [<a href="#rid125">125</a>]. (See  <a class="medical medical_review" href="/d/html/2813.html" rel="external">"Cancer-related fatigue: Treatment", section on 'General approach'</a>.)</p><p>Even when asked, patients may be hesitant to report fatigue to their healthcare provider [<a href="#rid5">5,126</a>]. Patients may believe that fatigue is an expected and inevitable side effect of treatment [<a href="#rid16">16,127</a>], fear that they will be labeled a "complainer," or be afraid that they will receive suboptimal cancer treatment if they admit to being fatigued. Patients also may be anxious because they believe that fatigue is a sign of recurrent or progressing disease.</p><p class="headingAnchor" id="H12"><span class="h1">CLINICAL ASSESSMENT</span></p><p class="headingAnchor" id="H434345"><span class="h2">Need for focused evaluation</span><span class="headingEndMark"> — </span>The need for a further fatigue-focused clinical evaluation is based upon the level of CRF.</p><p class="bulletIndent1"><span class="glyph">●</span>If the reported intensity level is mild (visual analog scale [VAS] or Brief Fatigue Inventory [BFI] score 1 to 3) and does not interfere with the activities of daily living (ADLs), focused fatigue evaluation is not needed. The patient can be reassured and educated as to some common strategies to minimize energy expenditure  (<a class="graphic graphic_table graphicRef73183" href="/d/graphic/73183.html" rel="external">table 6</a>). ADLs includes basic activities such as bathing, dressing, grooming, toileting, continence, eating, transferring and walking, as well as "instrumental" ADLs (IADLs) such as traveling, shopping, preparing meals, doing housework, taking medications, managing money, and using the telephone.</p><p></p><p class="bulletIndent1">Periodic reassessment should be undertaken. Patients who are no longer receiving active therapy as well as long-term cancer survivors must still be monitored for CRF, which may persist beyond the period of active treatment. If fatigue worsens, a focused fatigue assessment should then be undertaken.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Moderate to severe CRF (as defined by a score ≥4 on a scale of 1 to 10) is associated with significantly greater symptom interference compared with mild fatigue [<a href="#rid128">128</a>]. It requires a more focused history and physical examination to search for potentially reversible or treatable contributory factors.</p><p></p><p class="headingAnchor" id="H434397"><span class="h2">Components</span><span class="headingEndMark"> — </span>The components of an in-depth fatigue assessment include a focused fatigue history, an assessment of disease status and potentially treatable contributory factors, and appropriate referrals to trained professionals (eg, cardiologist, endocrinologist, mental health professional, internist) as needed [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H434403"><span class="h3">History</span><span class="headingEndMark"> — </span>A focused fatigue history includes the onset, duration, and pattern of fatigue, and associated or alleviating factors [<a href="#rid6">6</a>]. The effect of CRF on physical and cognitive functioning and on the patient's ADLs or enjoyment of life should be noted. A comprehensive review of systems is warranted to ascertain the various organ systems affected and to direct the physical examination and diagnostic work-up. Additional relevant information includes a history of smoking, alcohol and any illicit drug use, work history, and review of activity level and exercise tolerance.</p><p class="headingAnchor" id="H16"><span class="h3">Assessment of disease status</span><span class="headingEndMark"> — </span>Accurate assessment of the patient's current disease status, type of treatment, and response to treatment is an important component of the initial evaluation. The risk of recurrence can be estimated based upon stage, pathologic factors, and treatment history [<a href="#rid6">6</a>]. The review of symptoms may reveal other symptoms that substantiate suspicion for recurrence. If it is determined that fatigue is unrelated to disease progression or recurrence, informing patients and their family members of this fact may substantially reduce anxiety levels.</p><p class="headingAnchor" id="H434616"><span class="h3">Assess for potentially remediable contributing factors</span><span class="headingEndMark"> — </span>Factors that are often causally related to CRF should be specifically assessed, including anemia, unrelieved pain, emotional distress, sleep disturbance, nutritional issues and electrolyte disturbances, decreased activity level/deconditioning, alcohol and other substance abuse, and the presence of cardiac, endocrine, pulmonary, hepatic, and renal dysfunction [<a href="#rid6">6</a>]. A recommended approach to initial laboratory evaluation is outlined in the table  (<a class="graphic graphic_table graphicRef64018" href="/d/graphic/64018.html" rel="external">table 7</a>).</p><p>Comorbidities that may be unrelated to the cancer or its treatment (eg, infection, cardiopulmonary, renal, hepatic, neurologic, or endocrine dysfunction) may contribute significantly to symptoms of fatigue. CRF may be improved by optimizing treatment for conditions that have been previously unrecognized (eg, hypothyroidism) or suboptimally treated (eg, recurrent heart failure because of doxorubicin-induced cardiomyopathy). Hypothyroidism is particularly prevalent and may be related to irradiation for lymphoma, head and neck cancer, breast cancer, or total body irradiation prior to hematopoietic stem cell transplantation. In addition, several anticancer drugs (most notably <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a> and <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>) can cause hypothyroidism.</p><p>Potential comorbid conditions and other treatable contributory factors that may be associated with fatigue symptoms, and suggested diagnostic evaluation strategies are provided in the table  (<a class="graphic graphic_table graphicRef94933" href="/d/graphic/94933.html" rel="external">table 8</a>).</p><p>If any of these factors known to be associated with CRF are identified, they should be treated as the initial approach to fatigue. The clinical team must decide when/if referral to an appropriate professional is needed.</p><p class="headingAnchor" id="H8910329"><span class="h3">Medications</span><span class="headingEndMark"> — </span>Medications are an often overlooked major contributor to fatigue. Review of all medications (both prescribed and over the counter) may reveal potential side effects or drug-drug interactions. As examples, beta-blockers can cause bradycardia and exertional fatigue, while excessive drowsiness may result from combinations of opioids with antidepressants or antihistamines, or incorrectly dosed pain medications. In some cases, altering the dose or dosing interval of a medication may substantially improve fatigue. (See  <a class="medical medical_review" href="/d/html/2800.html" rel="external">"Prevention and management of side effects in patients receiving opioids for chronic pain", section on 'Somnolence and mental clouding'</a>.)</p><p class="headingAnchor" id="H8910308"><span class="h3">Activity level</span><span class="headingEndMark"> — </span>Patients with moderate to severe CRF should be asked about their overall activity level, including the influence of deconditioning. Patients should be asked whether they are able to maintain their basic and instrumental ADLs and whether they participate in either formal or informal exercise programs. Although exercise may be beneficial in improving CRF in certain patients, the level of deconditioning must be assessed before recommending an exercise program. If a severely deconditioned patient begins an exercise program too rapidly, complications may develop (eg, muscle strain) that may leave them discouraged and increasingly fatigued. (See  <a class="medical medical_review" href="/d/html/2813.html" rel="external">"Cancer-related fatigue: Treatment", section on 'Exercise'</a>.)</p><p class="headingAnchor" id="H8910387"><span class="h3">Nutritional assessment</span><span class="headingEndMark"> — </span>Nutritional assessment should include an evaluation for weight gain or loss, changes in and impediments to adequate caloric intake, and fluid and electrolyte imbalances. Oral intake can be adversely affected by anorexia, nausea, vomiting, mucositis, odynophagia, bowel obstruction, or constipation. Imbalances in sodium, potassium, calcium, and magnesium may be associated with fatigue, which is potentially reversible with adequate supplementation  (<a class="graphic graphic_table graphicRef64018" href="/d/graphic/64018.html" rel="external">table 7</a>).</p><p>Efforts directed at improving or maintaining nutritional status can decrease or prevent CRF. Patients with poor dietary intake or decreased absorption may need further assessment by a nutritionist. Treatment-related side effects such as nausea, vomiting, or diarrhea should be minimized. A detailed discussion of cancer-associated anorexia and cachexia is provided elsewhere. (See  <a class="medical medical_review" href="/d/html/1151.html" rel="external">"Prevention of chemotherapy-induced nausea and vomiting in adults"</a> and  <a class="medical medical_review" href="/d/html/2824.html" rel="external">"Chemotherapy-associated diarrhea, constipation and intestinal perforation: pathogenesis, risk factors, and clinical presentation"</a> and  <a class="medical medical_review" href="/d/html/2817.html" rel="external">"Pathogenesis, clinical features, and assessment of cancer cachexia"</a> and  <a class="medical medical_review" href="/d/html/2816.html" rel="external">"Management of cancer anorexia/cachexia"</a>.)</p><p class="headingAnchor" id="H2283608957"><span class="h1">GUIDELINES FROM EXPERT GROUPS</span><span class="headingEndMark"> — </span>Guidelines for screening and assessment of adults with CRF during and after therapy are available from several expert groups, including the NCCN [<a href="#rid6">6,7,18</a>].</p><p>A year 2014 clinical practice guideline for screening, assessment, and management of fatigue in adult cancer survivors is available from ASCO; specific recommendations for screening and assessment are outlined in the table  (<a class="graphic graphic_table graphicRef94923" href="/d/graphic/94923.html" rel="external">table 9</a>) [<a href="#rid6">6</a>]. Pan-Canadian guidelines for screening and assessment of CRF, which cover both survivors and patients undergoing active treatment, are also available  (<a class="graphic graphic_table graphicRef94934" href="/d/graphic/94934.html" rel="external">table 10</a>) [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H2083466"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/16250.html" rel="external">"Patient education: When your cancer treatment makes you tired (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H24"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and presentation</strong> – Cancer-related fatigue (CRF) is a distressing, persistent, subjective sense of physical, emotional and/or cognitive tiredness or exhaustion related to cancer or cancer treatment that is not proportional to recent activity and that significantly interferes with usual functioning [<a href="#rid6">6</a>]. Although most common during active cancer therapy, CRF may affect patients long after cancer treatment has been completed. (See <a class="local">'Definition'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>All patients with malignant disease should be screened for CRF at the initial visit, at the end of primary therapy, as clinically indicated (and at least annually) during follow-up survivor care, when the diagnosis of advanced disease is made, and at each chemotherapy visit.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Quantitative or semiquantitative instruments should be used. One example is a visual analog scale (VAS), "How would you rate your fatigue on a scale of 0 to 10?", with 0 representing no fatigue and 10 the worst imaginable fatigue. Mild, moderate, and severe fatigue are represented by scores of 1 to 3, 4 to 6, and 7 to 10, respectively. (See <a class="local">'Screening'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic evaluation</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with mild CRF (VAS score 1 to 3) that does not interfere with activities of daily living (ADLs) can be reassured and counseled as to coping strategies that conserve energy  (<a class="graphic graphic_table graphicRef73183" href="/d/graphic/73183.html" rel="external">table 6</a>). CRF that is moderate to severe (4 or higher on the VAS scale) or interferes with basic or instrumental ADLs requires a focused fatigue evaluation. (See <a class="local">'Need for focused evaluation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The evaluation should include a focused fatigue history, an assessment of disease status, review of all (prescription and over the counter) medications, assessment of activity levels, and nutritional assessment. (See <a class="local">'Components'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Factors that are often causally related to CRF that should be specifically assessed include anemia, pain (and its treatment), emotional distress/mood disturbance, sleep difficulties, poor nutrition and electrolyte disturbances, activity level, comorbidities such as cardiopulmonary or endocrine dysfunction, and hypogonadism  (<a class="graphic graphic_table graphicRef94933" href="/d/graphic/94933.html" rel="external">table 8</a>). A suggested initial laboratory evaluation is suggested in the table  (<a class="graphic graphic_table graphicRef64018" href="/d/graphic/64018.html" rel="external">table 7</a>). (See <a class="local">'Assess for potentially remediable contributing factors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If any of these factors known to be associated with CRF are identified, they should be treated as the initial approach to fatigue. The clinical team must decide when/if referral to an appropriate professional is needed.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bower JE, Ganz PA, Desmond KA, et al. Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. J Clin Oncol 2000; 18:743.</a></li><li><a class="nounderline abstract_t">Servaes P, Verhagen S, Bleijenberg G. Determinants of chronic fatigue in disease-free breast cancer patients: a cross-sectional study. Ann Oncol 2002; 13:589.</a></li><li><a class="nounderline abstract_t">Dagnelie PC, Pijls-Johannesma MC, Lambin P, et al. Impact of fatigue on overall quality of life in lung and breast cancer patients selected for high-dose radiotherapy. Ann Oncol 2007; 18:940.</a></li><li><a class="nounderline abstract_t">Gupta D, Lis CG, Grutsch JF. The relationship between cancer-related fatigue and patient satisfaction with quality of life in cancer. J Pain Symptom Manage 2007; 34:40.</a></li><li><a class="nounderline abstract_t">Stone P, Richardson A, Ream E, et al. Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum. Ann Oncol 2000; 11:971.</a></li><li><a class="nounderline abstract_t">Bower JE, Bak K, Berger A, et al. Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical Oncology clinical practice guideline adaptation. J Clin Oncol 2014; 32:1840.</a></li><li><a class="nounderline abstract_t">Howell D, Keller-Olaman S, Oliver TK, et al. A pan-Canadian practice guideline and algorithm: screening, assessment, and supportive care of adults with cancer-related fatigue. Curr Oncol 2013; 20:e233.</a></li><li><a class="nounderline abstract_t">Mitchell SA, Beck SL, Hood LE, et al. Putting evidence into practice: evidence-based interventions for fatigue during and following cancer and its treatment. Clin J Oncol Nurs 2007; 11:99.</a></li><li><a class="nounderline abstract_t">Sobrero A, Puglisi F, Guglielmi A, et al. Fatigue: a main component of anemia symptomatology. Semin Oncol 2001; 28:15.</a></li><li><a class="nounderline abstract_t">Cella D, Peterman A, Passik S, et al. Progress toward guidelines for the management of fatigue. Oncology (Williston Park) 1998; 12:369.</a></li><li class="breakAll">International Classification of Diseases, Tenth Revision (ICD-10). www.cdc.gov/nchs/about/major/dvs/icd10des.htm (Accessed on February 28, 2012).</li><li><a class="nounderline abstract_t">Cella D, Davis K, Breitbart W, et al. Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol 2001; 19:3385.</a></li><li><a class="nounderline abstract_t">Andrykowski MA, Schmidt JE, Salsman JM, et al. Use of a case definition approach to identify cancer-related fatigue in women undergoing adjuvant therapy for breast cancer. J Clin Oncol 2005; 23:6613.</a></li><li><a class="nounderline abstract_t">Sadler IJ, Jacobsen PB, Booth-Jones M, et al. Preliminary evaluation of a clinical syndrome approach to assessing cancer-related fatigue. J Pain Symptom Manage 2002; 23:406.</a></li><li><a class="nounderline abstract_t">Murphy H, Alexander S, Stone P. Investigation of diagnostic criteria for cancer-related fatigue syndrome in patients with advanced cancer: a feasibility study. Palliat Med 2006; 20:413.</a></li><li><a class="nounderline abstract_t">Vogelzang NJ, Breitbart W, Cella D, et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 1997; 34:4.</a></li><li><a class="nounderline abstract_t">Curt GA, Breitbart W, Cella D, et al. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 2000; 5:353.</a></li><li class="breakAll">NCCN Guidelines for Cancer related fatigue (v1.2022) availabe online at https://www.nccn.org/guidelines/ (Accessed on January 21, 2022).</li><li><a class="nounderline abstract_t">Vaz-Luis I, Di Meglio A, Havas J, et al. Long-Term Longitudinal Patterns of Patient-Reported Fatigue After Breast Cancer: A Group-Based Trajectory Analysis. J Clin Oncol 2022; 40:2148.</a></li><li><a class="nounderline abstract_t">Stasi R, Abriani L, Beccaglia P, et al. Cancer-related fatigue: evolving concepts in evaluation and treatment. Cancer 2003; 98:1786.</a></li><li><a class="nounderline abstract_t">Flechtner H, Bottomley A. Fatigue and quality of life: lessons from the real world. Oncologist 2003; 8 Suppl 1:5.</a></li><li><a class="nounderline abstract_t">de Jong N, Courtens AM, Abu-Saad HH, Schouten HC. Fatigue in patients with breast cancer receiving adjuvant chemotherapy: a review of the literature. Cancer Nurs 2002; 25:283.</a></li><li><a class="nounderline abstract_t">Morrow GR, Andrews PL, Hickok JT, et al. Fatigue associated with cancer and its treatment. Support Care Cancer 2002; 10:389.</a></li><li><a class="nounderline abstract_t">Holzner B, Kemmler G, Meraner V, et al. Fatigue in ovarian carcinoma patients: a neglected issue? Cancer 2003; 97:1564.</a></li><li><a class="nounderline abstract_t">Respini D, Jacobsen PB, Thors C, et al. The prevalence and correlates of fatigue in older cancer patients. Crit Rev Oncol Hematol 2003; 47:273.</a></li><li><a class="nounderline abstract_t">Wang XS, Giralt SA, Mendoza TR, et al. Clinical factors associated with cancer-related fatigue in patients being treated for leukemia and non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:1319.</a></li><li><a class="nounderline abstract_t">Edwards JL, Gibson F, Richardson A, et al. Fatigue in adolescents with and following a cancer diagnosis: developing an evidence base for practice. Eur J Cancer 2003; 39:2671.</a></li><li><a class="nounderline abstract_t">Fernandes R, Stone P, Andrews P, et al. Comparison between fatigue, sleep disturbance, and circadian rhythm in cancer inpatients and healthy volunteers: evaluation of diagnostic criteria for cancer-related fatigue. J Pain Symptom Manage 2006; 32:245.</a></li><li><a class="nounderline abstract_t">Chang VT, Hwang SS, Feuerman M, Kasimis BS. Symptom and quality of life survey of medical oncology patients at a veterans affairs medical center: a role for symptom assessment. Cancer 2000; 88:1175.</a></li><li><a class="nounderline abstract_t">Smets EM, Visser MR, Willems-Groot AF, et al. Fatigue and radiotherapy: (A) experience in patients undergoing treatment. Br J Cancer 1998; 78:899.</a></li><li><a class="nounderline abstract_t">Hickok JT, Morrow GR, McDonald S, Bellg AJ. Frequency and correlates of fatigue in lung cancer patients receiving radiation therapy: implications for management. J Pain Symptom Manage 1996; 11:370.</a></li><li><a class="nounderline abstract_t">Liavaag AH, Dørum A, Fosså SD, et al. Controlled study of fatigue, quality of life, and somatic and mental morbidity in epithelial ovarian cancer survivors: how lucky are the lucky ones? J Clin Oncol 2007; 25:2049.</a></li><li><a class="nounderline abstract_t">Teunissen SC, Wesker W, Kruitwagen C, et al. Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manage 2007; 34:94.</a></li><li><a class="nounderline abstract_t">Stone P, Hardy J, Broadley K, et al. Fatigue in advanced cancer: a prospective controlled cross-sectional study. Br J Cancer 1999; 79:1479.</a></li><li><a class="nounderline abstract_t">Eatock MM, Dillon E, Corcoran B, et al. Cancer fatigue in Ireland: All Ireland Fatigue Coalition professional and interim patient survey. Proc Am Soc Clin Oncol 2003; 22:764a.</a></li><li><a class="nounderline abstract_t">Forlenza MJ, Hall P, Lichtenstein P, et al. Epidemiology of cancer-related fatigue in the Swedish twin registry. Cancer 2005; 104:2022.</a></li><li><a class="nounderline abstract_t">Janda M, Gerstner N, Obermair A, et al. Quality of life changes during conformal radiation therapy for prostate carcinoma. Cancer 2000; 89:1322.</a></li><li><a class="nounderline abstract_t">Greenberg DB, Sawicka J, Eisenthal S, Ross D. Fatigue syndrome due to localized radiation. J Pain Symptom Manage 1992; 7:38.</a></li><li><a class="nounderline abstract_t">Geinitz H, Zimmermann FB, Stoll P, et al. Fatigue, serum cytokine levels, and blood cell counts during radiotherapy of patients with breast cancer. Int J Radiat Oncol Biol Phys 2001; 51:691.</a></li><li><a class="nounderline abstract_t">Irvine DM, Vincent L, Graydon JE, Bubela N. Fatigue in women with breast cancer receiving radiation therapy. Cancer Nurs 1998; 21:127.</a></li><li><a class="nounderline abstract_t">Smets EM, Visser MR, Willems-Groot AF, et al. Fatigue and radiotherapy: (B) experience in patients 9 months following treatment. Br J Cancer 1998; 78:907.</a></li><li><a class="nounderline abstract_t">Monga U, Kerrigan AJ, Thornby J, Monga TN. Prospective study of fatigue in localized prostate cancer patients undergoing radiotherapy. Radiat Oncol Investig 1999; 7:178.</a></li><li><a class="nounderline abstract_t">Magnan MA, Mood DW. The effects of health state, hemoglobin, global symptom distress, mood disturbance, and treatment site on fatigue onset, duration, and distress in patients receiving radiation therapy. Oncol Nurs Forum 2003; 30:E33.</a></li><li><a class="nounderline abstract_t">Servaes P, Verhagen S, Schreuder HW, et al. Fatigue after treatment for malignant and benign bone and soft tissue tumors. J Pain Symptom Manage 2003; 26:1113.</a></li><li><a class="nounderline abstract_t">Rüffer JU, Flechtner H, Tralls P, et al. Fatigue in long-term survivors of Hodgkin's lymphoma; a report from the German Hodgkin Lymphoma Study Group (GHSG). Eur J Cancer 2003; 39:2179.</a></li><li><a class="nounderline abstract_t">Fosså SD, Dahl AA, Loge JH. Fatigue, anxiety, and depression in long-term survivors of testicular cancer. J Clin Oncol 2003; 21:1249.</a></li><li><a class="nounderline abstract_t">Arndt V, Merx H, Stegmaier C, et al. Persistence of restrictions in quality of life from the first to the third year after diagnosis in women with breast cancer. J Clin Oncol 2005; 23:4945.</a></li><li><a class="nounderline abstract_t">Meeske K, Smith AW, Alfano CM, et al. Fatigue in breast cancer survivors two to five years post diagnosis: a HEAL Study report. Qual Life Res 2007; 16:947.</a></li><li><a class="nounderline abstract_t">Loge JH, Abrahamsen AF, Ekeberg O, Kaasa S. Hodgkin's disease survivors more fatigued than the general population. J Clin Oncol 1999; 17:253.</a></li><li><a class="nounderline abstract_t">Andrykowski MA, Curran SL, Lightner R. Off-treatment fatigue in breast cancer survivors: a controlled comparison. J Behav Med 1998; 21:1.</a></li><li><a class="nounderline abstract_t">Hjermstad MJ, Fosså SD, Oldervoll L, et al. Fatigue in long-term Hodgkin's Disease survivors: a follow-up study. J Clin Oncol 2005; 23:6587.</a></li><li><a class="nounderline abstract_t">Jacobsen PB, Donovan KA, Small BJ, et al. Fatigue after treatment for early stage breast cancer: a controlled comparison. Cancer 2007; 110:1851.</a></li><li><a class="nounderline abstract_t">Braun IM, Greenberg DB, Pirl WF. Evidenced-based report on the occurrence of fatigue in long-term cancer survivors. J Natl Compr Canc Netw 2008; 6:347.</a></li><li><a class="nounderline abstract_t">Daniëls LA, Oerlemans S, Krol AD, et al. Chronic fatigue in Hodgkin lymphoma survivors and associations with anxiety, depression and comorbidity. Br J Cancer 2014; 110:868.</a></li><li><a class="nounderline abstract_t">Gutstein HB. The biologic basis of fatigue. Cancer 2001; 92:1678.</a></li><li><a class="nounderline abstract_t">Lundström S, Fürst CJ. Symptoms in advanced cancer: relationship to endogenous cortisol levels. Palliat Med 2003; 17:503.</a></li><li><a class="nounderline abstract_t">Scott HR, McMillan DC, Brown DJ, et al. A prospective study of the impact of weight loss and the systemic inflammatory response on quality of life in patients with inoperable non-small cell lung cancer. Lung Cancer 2003; 40:295.</a></li><li><a class="nounderline abstract_t">Cleeland CS, Bennett GJ, Dantzer R, et al. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer 2003; 97:2919.</a></li><li><a class="nounderline abstract_t">Scott HR, McMillan DC, Forrest LM, et al. The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br J Cancer 2002; 87:264.</a></li><li><a class="nounderline abstract_t">Collado-Hidalgo A, Bower JE, Ganz PA, et al. Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clin Cancer Res 2006; 12:2759.</a></li><li><a class="nounderline abstract_t">Bower JE, Ganz PA, Aziz N, Fahey JL. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom Med 2002; 64:604.</a></li><li><a class="nounderline abstract_t">Bower JE, Ganz PA, Irwin MR, et al. Cytokine genetic variations and fatigue among patients with breast cancer. J Clin Oncol 2013; 31:1656.</a></li><li><a class="nounderline abstract_t">Bower JE, Ganz PA, Aziz N, et al. T-cell homeostasis in breast cancer survivors with persistent fatigue. J Natl Cancer Inst 2003; 95:1165.</a></li><li><a class="nounderline abstract_t">Parker KP, Bliwise DL, Ribeiro M, et al. Sleep/Wake patterns of individuals with advanced cancer measured by ambulatory polysomnography. J Clin Oncol 2008; 26:2464.</a></li><li><a class="nounderline abstract_t">Ancoli-Israel S, Moore PJ, Jones V. The relationship between fatigue and sleep in cancer patients: a review. Eur J Cancer Care (Engl) 2001; 10:245.</a></li><li><a class="nounderline abstract_t">Miaskowski C, Lee KA. Pain, fatigue, and sleep disturbances in oncology outpatients receiving radiation therapy for bone metastasis: a pilot study. J Pain Symptom Manage 1999; 17:320.</a></li><li><a class="nounderline abstract_t">Roscoe JA, Morrow GR, Hickok JT, et al. Temporal interrelationships among fatigue, circadian rhythm and depression in breast cancer patients undergoing chemotherapy treatment. Support Care Cancer 2002; 10:329.</a></li><li><a class="nounderline abstract_t">Savard J, Davidson JR, Ivers H, et al. The association between nocturnal hot flashes and sleep in breast cancer survivors. J Pain Symptom Manage 2004; 27:513.</a></li><li><a class="nounderline abstract_t">Levy MR. Cancer fatigue: a neurobiological review for psychiatrists. Psychosomatics 2008; 49:283.</a></li><li><a class="nounderline abstract_t">Ryan JL, Carroll JK, Ryan EP, et al. Mechanisms of cancer-related fatigue. Oncologist 2007; 12 Suppl 1:22.</a></li><li><a class="nounderline abstract_t">Saligan LN, Olson K, Filler K, et al. The biology of cancer-related fatigue: a review of the literature. Support Care Cancer 2015; 23:2461.</a></li><li><a class="nounderline abstract_t">Stone P, Richards M, Hardy J. Fatigue in patients with cancer. Eur J Cancer 1998; 34:1670.</a></li><li><a class="nounderline abstract_t">Tchen N, Juffs HG, Downie FP, et al. Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol 2003; 21:4175.</a></li><li><a class="nounderline abstract_t">Fan HG, Houédé-Tchen N, Yi QL, et al. Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study. J Clin Oncol 2005; 23:8025.</a></li><li><a class="nounderline abstract_t">Nieboer P, Buijs C, Rodenhuis S, et al. Fatigue and relating factors in high-risk breast cancer patients treated with adjuvant standard or high-dose chemotherapy: a longitudinal study. J Clin Oncol 2005; 23:8296.</a></li><li><a class="nounderline abstract_t">Knobel H, Håvard Loge J, Lund MB, et al. Late medical complications and fatigue in Hodgkin's disease survivors. J Clin Oncol 2001; 19:3226.</a></li><li><a class="nounderline abstract_t">Kirkwood JM, Bender C, Agarwala S, et al. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol 2002; 20:3703.</a></li><li><a class="nounderline abstract_t">Sundin DJ, Wolin MJ. Toxicity management in patients receiving low-dose aldesleukin therapy. Ann Pharmacother 1998; 32:1344.</a></li><li><a class="nounderline abstract_t">Malik UR, Makower DF, Wadler S. Interferon-mediated fatigue. Cancer 2001; 92:1664.</a></li><li><a class="nounderline abstract_t">Englebienne P, Verhas M, Herst CV, De Meirleir K. Type I interferons induce proteins susceptible to act as thyroid receptor (TR) corepressors and to signal the TR for destruction by the proteasome: possible etiology for unexplained chronic fatigue. Med Hypotheses 2003; 60:175.</a></li><li><a class="nounderline abstract_t">Jones TH, Wadler S, Hupart KH. Endocrine-mediated mechanisms of fatigue during treatment with interferon-alpha. Semin Oncol 1998; 25:54.</a></li><li><a class="nounderline abstract_t">Atkins MB, Mier JW, Parkinson DR, et al. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med 1988; 318:1557.</a></li><li><a class="nounderline abstract_t">Weijl NI, Van der Harst D, Brand A, et al. Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment. J Clin Oncol 1993; 11:1376.</a></li><li><a class="nounderline abstract_t">Light KC, Agarwal N, Iacob E, et al. Differing leukocyte gene expression profiles associated with fatigue in patients with prostate cancer versus chronic fatigue syndrome. Psychoneuroendocrinology 2013; 38:2983.</a></li><li><a class="nounderline abstract_t">Jim HS, Park JY, Permuth-Wey J, et al. Genetic predictors of fatigue in prostate cancer patients treated with androgen deprivation therapy: preliminary findings. Brain Behav Immun 2012; 26:1030.</a></li><li><a class="nounderline abstract_t">Jereczek-Fossa BA, Marsiglia HR, Orecchia R. Radiotherapy-related fatigue. Crit Rev Oncol Hematol 2002; 41:317.</a></li><li><a class="nounderline abstract_t">Brown P, Clark MM, Atherton P, et al. Will improvement in quality of life (QOL) impact fatigue in patients receiving radiation therapy for advanced cancer? Am J Clin Oncol 2006; 29:52.</a></li><li><a class="nounderline abstract_t">Hickok JT, Morrow GR, Roscoe JA, et al. Occurrence, severity, and longitudinal course of twelve common symptoms in 1129 consecutive patients during radiotherapy for cancer. J Pain Symptom Manage 2005; 30:433.</a></li><li><a class="nounderline abstract_t">Ahlberg K, Ekman T, Gaston-Johansson F. Levels of fatigue compared to levels of cytokines and hemoglobin during pelvic radiotherapy: a pilot study. Biol Res Nurs 2004; 5:203.</a></li><li><a class="nounderline abstract_t">Wang XS, Janjan NA, Guo H, et al. Fatigue during preoperative chemoradiation for resectable rectal cancer. Cancer 2001; 92:1725.</a></li><li><a class="nounderline abstract_t">Jereczek-Fossa BA, Santoro L, Alterio D, et al. Fatigue during head-and-neck radiotherapy: prospective study on 117 consecutive patients. Int J Radiat Oncol Biol Phys 2007; 68:403.</a></li><li><a class="nounderline abstract_t">Monga U, Jaweed M, Kerrigan AJ, et al. Neuromuscular fatigue in prostate cancer patients undergoing radiation therapy. Arch Phys Med Rehabil 1997; 78:961.</a></li><li><a class="nounderline abstract_t">Yellen SB, Cella DF, Webster K, et al. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 1997; 13:63.</a></li><li><a class="nounderline abstract_t">Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997; 34:13.</a></li><li><a class="nounderline abstract_t">Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001; 19:2875.</a></li><li><a class="nounderline abstract_t">Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002; 94:1211.</a></li><li><a class="nounderline abstract_t">Cella D, Zagari MJ, Vandoros C, et al. Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. J Clin Oncol 2003; 21:366.</a></li><li><a class="nounderline abstract_t">Escalante CP, Grover T, Johnson BA, et al. A fatigue clinic in a comprehensive cancer center: design and experiences. Cancer 2001; 92:1708.</a></li><li><a class="nounderline abstract_t">Jacobsen PB, Hann DM, Azzarello LM, et al. Fatigue in women receiving adjuvant chemotherapy for breast cancer: characteristics, course, and correlates. J Pain Symptom Manage 1999; 18:233.</a></li><li><a class="nounderline abstract_t">Dodd MJ, Miaskowski C, Paul SM. Symptom clusters and their effect on the functional status of patients with cancer. Oncol Nurs Forum 2001; 28:465.</a></li><li><a class="nounderline abstract_t">Romito F, Montanaro R, Corvasce C, et al. Is cancer-related fatigue more strongly correlated to haematological or to psychological factors in cancer patients? Support Care Cancer 2008; 16:943.</a></li><li><a class="nounderline abstract_t">Goldstein D, Bennett B, Friedlander M, et al. Fatigue states after cancer treatment occur both in association with, and independent of, mood disorder: a longitudinal study. BMC Cancer 2006; 6:240.</a></li><li><a class="nounderline abstract_t">Broeckel JA, Jacobsen PB, Horton J, et al. Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer. J Clin Oncol 1998; 16:1689.</a></li><li><a class="nounderline abstract_t">Ahlberg K, Ekman T, Wallgren A, Gaston-Johansson F. Fatigue, psychological distress, coping and quality of life in patients with uterine cancer. J Adv Nurs 2004; 45:205.</a></li><li><a class="nounderline abstract_t">Tchekmedyian NS, Kallich J, McDermott A, et al. The relationship between psychologic distress and cancer-related fatigue. Cancer 2003; 98:198.</a></li><li><a class="nounderline abstract_t">Haghighat S, Akbari ME, Holakouei K, et al. Factors predicting fatigue in breast cancer patients. Support Care Cancer 2003; 11:533.</a></li><li><a class="nounderline abstract_t">Hwang SS, Chang VT, Rue M, Kasimis B. Multidimensional independent predictors of cancer-related fatigue. J Pain Symptom Manage 2003; 26:604.</a></li><li><a class="nounderline abstract_t">Jacobsen PB, Donovan KA, Weitzner MA. Distinguishing fatigue and depression in patients with cancer. Semin Clin Neuropsychiatry 2003; 8:229.</a></li><li><a class="nounderline abstract_t">Passik SD, Dugan W, McDonald MV, et al. Oncologists' recognition of depression in their patients with cancer. J Clin Oncol 1998; 16:1594.</a></li><li><a class="nounderline abstract_t">Visser MR, Smets EM. Fatigue, depression and quality of life in cancer patients: how are they related? Support Care Cancer 1998; 6:101.</a></li><li><a class="nounderline abstract_t">Morrow GR, Jean-Pierre P, Roscoe JA, et AL. A phase III randomized, placebo-controlled, double-blind trial of a eugeroic agent in 642 cancer patients reporting fatigue during chemotherapy: a URCC CCOP study. J Clin Oncol 2008; 26S:ASCO #9512.</a></li><li><a class="nounderline abstract_t">Mystakidou K, Parpa E, Tsilika E, et al. The relationship of subjective sleep quality, pain, and quality of life in advanced cancer patients. Sleep 2007; 30:737.</a></li><li><a class="nounderline abstract_t">Silberfarb PM, Hauri PJ, Oxman TE, Schnurr P. Assessment of sleep in patients with lung cancer and breast cancer. J Clin Oncol 1993; 11:997.</a></li><li><a class="nounderline abstract_t">Savard J, Morin CM. Insomnia in the context of cancer: a review of a neglected problem. J Clin Oncol 2001; 19:895.</a></li><li><a class="nounderline abstract_t">Savard J, Simard S, Blanchet J, et al. Prevalence, clinical characteristics, and risk factors for insomnia in the context of breast cancer. Sleep 2001; 24:583.</a></li><li><a class="nounderline abstract_t">Savard J, Simard S, Hervouet S, et al. Insomnia in men treated with radical prostatectomy for prostate cancer. Psychooncology 2005; 14:147.</a></li><li><a class="nounderline abstract_t">Savard J, Villa J, Ivers H, et al. Prevalence, natural course, and risk factors of insomnia comorbid with cancer over a 2-month period. J Clin Oncol 2009; 27:5233.</a></li><li><a class="nounderline abstract_t">Palesh OG, Roscoe JA, Mustian KM, et al. Prevalence, demographics, and psychological associations of sleep disruption in patients with cancer: University of Rochester Cancer Center-Community Clinical Oncology Program. J Clin Oncol 2010; 28:292.</a></li><li><a class="nounderline abstract_t">Otte JL, Carpenter JS, Russell KM, et al. Prevalence, severity, and correlates of sleep-wake disturbances in long-term breast cancer survivors. J Pain Symptom Manage 2010; 39:535.</a></li><li><a class="nounderline abstract_t">Mendoza TR, Wang XS, Cleeland CS, et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer 1999; 85:1186.</a></li><li><a class="nounderline abstract_t">Alexander S, Minton O, Stone PC. Evaluation of screening instruments for cancer-related fatigue syndrome in breast cancer survivors. J Clin Oncol 2009; 27:1197.</a></li><li><a class="nounderline abstract_t">Chalder T, Berelowitz G, Pawlikowska T, et al. Development of a fatigue scale. J Psychosom Res 1993; 37:147.</a></li><li><a class="nounderline abstract_t">Stein KD, Jacobsen PB, Blanchard CM, Thors C. Further validation of the multidimensional fatigue symptom inventory-short form. J Pain Symptom Manage 2004; 27:14.</a></li><li><a class="nounderline abstract_t">Minton O, Stone P. A systematic review of the scales used for the measurement of cancer-related fatigue (CRF). Ann Oncol 2009; 20:17.</a></li><li><a class="nounderline abstract_t">Basch E, Schrag D, Henson S, et al. Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer: A Randomized Clinical Trial. JAMA 2022; 327:2413.</a></li><li><a class="nounderline abstract_t">Passik SD, Kirsh KL, Donaghy K, et al. Patient-related barriers to fatigue communication: initial validation of the fatigue management barriers questionnaire. J Pain Symptom Manage 2002; 24:481.</a></li><li><a class="nounderline abstract_t">Patrick DL, Ferketich SL, Frame PS, et al. National Institutes of Health State-of-the-Science Conference Statement: Symptom Management in Cancer: Pain, Depression, and Fatigue, July 15-17, 2002. J Natl Cancer Inst 2003; 95:1110.</a></li><li><a class="nounderline abstract_t">Wang XS, Zhao F, Fisch MJ, et al. Prevalence and characteristics of moderate to severe fatigue: a multicenter study in cancer patients and survivors. Cancer 2014; 120:425.</a></li></ol></div><div id="topicVersionRevision">Topic 2802 Version 33.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10673515" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12056710" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Determinants of chronic fatigue in disease-free breast cancer patients: a cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17363839" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Impact of fatigue on overall quality of life in lung and breast cancer patients selected for high-dose radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17532179" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The relationship between cancer-related fatigue and patient satisfaction with quality of life in cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11038033" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24733803" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical Oncology clinical practice guideline adaptation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23737693" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A pan-Canadian practice guideline and algorithm: screening, assessment, and supportive care of adults with cancer-related fatigue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17441401" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Putting evidence into practice: evidence-based interventions for fatigue during and following cancer and its treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11395847" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Fatigue: a main component of anemia symptomatology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10028520" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Progress toward guidelines for the management of fatigue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10028520" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Progress toward guidelines for the management of fatigue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11454886" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16170168" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Use of a case definition approach to identify cancer-related fatigue in women undergoing adjuvant therapy for breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12007758" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Preliminary evaluation of a clinical syndrome approach to assessing cancer-related fatigue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16875111" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Investigation of diagnostic criteria for cancer-related fatigue syndrome in patients with advanced cancer: a feasibility study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9253778" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11040270" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11040270" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35290073" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Long-Term Longitudinal Patterns of Patient-Reported Fatigue After Breast Cancer: A Group-Based Trajectory Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14584059" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Cancer-related fatigue: evolving concepts in evaluation and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12626781" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Fatigue and quality of life: lessons from the real world.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12181497" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Fatigue in patients with breast cancer receiving adjuvant chemotherapy: a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12136222" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Fatigue associated with cancer and its treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12627522" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Fatigue in ovarian carcinoma patients: a neglected issue?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12962901" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The prevalence and correlates of fatigue in older cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11870175" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Clinical factors associated with cancer-related fatigue in patients being treated for leukemia and non-Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14642930" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Fatigue in adolescents with and following a cancer diagnosis: developing an evidence base for practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16939849" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Comparison between fatigue, sleep disturbance, and circadian rhythm in cancer inpatients and healthy volunteers: evaluation of diagnostic criteria for cancer-related fatigue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10699909" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Symptom and quality of life survey of medical oncology patients at a veterans affairs medical center: a role for symptom assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9764581" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Fatigue and radiotherapy: (A) experience in patients undergoing treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8935141" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Frequency and correlates of fatigue in lung cancer patients receiving radiation therapy: implications for management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17513809" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Controlled study of fatigue, quality of life, and somatic and mental morbidity in epithelial ovarian cancer survivors: how lucky are the lucky ones?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17509812" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Symptom prevalence in patients with incurable cancer: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10188894" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Fatigue in advanced cancer: a prospective controlled cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Cancer fatigue in Ireland: All Ireland Fatigue Coalition professional and interim patient survey</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16206253" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Epidemiology of cancer-related fatigue in the Swedish twin registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11002229" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Quality of life changes during conformal radiation therapy for prostate carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1538180" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Fatigue syndrome due to localized radiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11597810" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Fatigue, serum cytokine levels, and blood cell counts during radiotherapy of patients with breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9556939" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Fatigue in women with breast cancer receiving radiation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9764582" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Fatigue and radiotherapy: (B) experience in patients 9 months following treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10406060" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Prospective study of fatigue in localized prostate cancer patients undergoing radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12692668" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The effects of health state, hemoglobin, global symptom distress, mood disturbance, and treatment site on fatigue onset, duration, and distress in patients receiving radiation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14654263" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Fatigue after treatment for malignant and benign bone and soft tissue tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14522376" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Fatigue in long-term survivors of Hodgkin's lymphoma; a report from the German Hodgkin Lymphoma Study Group (GHSG).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12663711" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Fatigue, anxiety, and depression in long-term survivors of testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16051947" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Persistence of restrictions in quality of life from the first to the third year after diagnosis in women with breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17457697" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Fatigue in breast cancer survivors two to five years post diagnosis: a HEAL Study report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10458240" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Hodgkin's disease survivors more fatigued than the general population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9547419" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Off-treatment fatigue in breast cancer survivors: a controlled comparison.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16170166" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Fatigue in long-term Hodgkin's Disease survivors: a follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17847016" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Fatigue after treatment for early stage breast cancer: a controlled comparison.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18433605" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Evidenced-based report on the occurrence of fatigue in long-term cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24434433" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Chronic fatigue in Hodgkin lymphoma survivors and associations with anxiety, depression and comorbidity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11598886" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The biologic basis of fatigue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14526883" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Symptoms in advanced cancer: relationship to endogenous cortisol levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12781428" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : A prospective study of the impact of weight loss and the systemic inflammatory response on quality of life in patients with inoperable non-small cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12767108" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12177792" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16675568" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Inflammatory biomarkers for persistent fatigue in breast cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12140350" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Fatigue and proinflammatory cytokine activity in breast cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23530106" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Cytokine genetic variations and fatigue among patients with breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12902446" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : T-cell homeostasis in breast cancer survivors with persistent fatigue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18487566" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Sleep/Wake patterns of individuals with advanced cancer measured by ambulatory polysomnography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11806675" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The relationship between fatigue and sleep in cancer patients: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10355211" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Pain, fatigue, and sleep disturbances in oncology outpatients receiving radiation therapy for bone metastasis: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12029433" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Temporal interrelationships among fatigue, circadian rhythm and depression in breast cancer patients undergoing chemotherapy treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15165649" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The association between nocturnal hot flashes and sleep in breast cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18621933" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Cancer fatigue: a neurobiological review for psychiatrists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17573453" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Mechanisms of cancer-related fatigue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25975676" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : The biology of cancer-related fatigue: a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9893650" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Fatigue in patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14615445" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16258100" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16219926" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Fatigue and relating factors in high-risk breast cancer patients treated with adjuvant standard or high-dose chemotherapy: a longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11432890" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Late medical complications and fatigue in Hodgkin's disease survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12202672" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9876817" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Toxicity management in patients receiving low-dose aldesleukin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11598884" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Interferon-mediated fatigue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12606231" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Type I interferons induce proteins susceptible to act as thyroid receptor (TR) corepressors and to signal the TR for destruction by the proteasome: possible etiology for unexplained chronic fatigue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9482541" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Endocrine-mediated mechanisms of fatigue during treatment with interferon-alpha.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3259674" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8315436" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24054763" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Differing leukocyte gene expression profiles associated with fatigue in patients with prostate cancer versus chronic fatigue syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22475653" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Genetic predictors of fatigue in prostate cancer patients treated with androgen deprivation therapy: preliminary findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11880207" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Radiotherapy-related fatigue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16462503" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Will improvement in quality of life (QOL) impact fatigue in patients receiving radiation therapy for advanced cancer?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16310617" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Occurrence, severity, and longitudinal course of twelve common symptoms in 1129 consecutive patients during radiotherapy for cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14737921" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Levels of fatigue compared to levels of cytokines and hemoglobin during pelvic radiotherapy: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11598894" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Fatigue during preoperative chemoradiation for resectable rectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17398020" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Fatigue during head-and-neck radiotherapy: prospective study on 117 consecutive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9305269" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Neuromuscular fatigue in prostate cancer patients undergoing radiation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9095563" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9253779" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11387360" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12189224" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12525531" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11598891" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : A fatigue clinic in a comprehensive cancer center: design and experiences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10534963" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Fatigue in women receiving adjuvant chemotherapy for breast cancer: characteristics, course, and correlates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11338755" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Symptom clusters and their effect on the functional status of patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18071764" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Is cancer-related fatigue more strongly correlated to haematological or to psychological factors in cancer patients?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17026776" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Fatigue states after cancer treatment occur both in association with, and independent of, mood disorder: a longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9586880" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14706006" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Fatigue, psychological distress, coping and quality of life in patients with uterine cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12833472" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : The relationship between psychologic distress and cancer-related fatigue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12730728" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Factors predicting fatigue in breast cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12850643" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Multidimensional independent predictors of cancer-related fatigue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14613050" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Distinguishing fatigue and depression in patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9552071" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Oncologists' recognition of depression in their patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9540167" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Fatigue, depression and quality of life in cancer patients: how are they related?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : A phase III randomized, placebo-controlled, double-blind trial of a eugeroic agent in 642 cancer patients reporting fatigue during chemotherapy: a URCC CCOP study</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17580595" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : The relationship of subjective sleep quality, pain, and quality of life in advanced cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8487063" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Assessment of sleep in patients with lung cancer and breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11157043" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Insomnia in the context of cancer: a review of a neglected problem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11480655" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Prevalence, clinical characteristics, and risk factors for insomnia in the context of breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15386779" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Insomnia in men treated with radical prostatectomy for prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19738124" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Prevalence, natural course, and risk factors of insomnia comorbid with cancer over a 2-month period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19933917" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Prevalence, demographics, and psychological associations of sleep disruption in patients with cancer: University of Rochester Cancer Center-Community Clinical Oncology Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20083371" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Prevalence, severity, and correlates of sleep-wake disturbances in long-term breast cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10091805" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19164208" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Evaluation of screening instruments for cancer-related fatigue syndrome in breast cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8463991" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Development of a fatigue scale.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14711465" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Further validation of the multidimensional fatigue symptom inventory-short form.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18678767" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : A systematic review of the scales used for the measurement of cancer-related fatigue (CRF).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35661856" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12547048" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Patient-related barriers to fatigue communication: initial validation of the fatigue management barriers questionnaire.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12902440" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : National Institutes of Health State-of-the-Science Conference Statement: Symptom Management in Cancer: Pain, Depression, and Fatigue, July 15-17, 2002.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24436136" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Prevalence and characteristics of moderate to severe fatigue: a multicenter study in cancer patients and survivors.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
